C
Charles H. Hennekens
Researcher at Harvard University
Publications - 439
Citations - 120693
Charles H. Hennekens is an academic researcher from Harvard University. The author has contributed to research in topics: Risk factor & Relative risk. The author has an hindex of 150, co-authored 424 publications receiving 117806 citations. Previous affiliations of Charles H. Hennekens include University of Auckland & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19
TL;DR: The first oral antiviral drug for the early treatment of COVID-19 was proposed by Coronavirus and Covid-19 as discussed by the authors , which contains two protease inhibitors, nirmatrelvir and ritonavir (Paxlovid, Pfizer).
Journal ArticleDOI
Cholesterol Lowering With Statin Drugs: Evidence in Women-Reply
TL;DR: It would be unusual to find qualitative differences between men and women in cardiovascular disease benefits in the ongoing primary prevention trials, and the overall results rather than sex-specific subgroup analyses provide the most reliable estimates of treatment effects.
Journal ArticleDOI
Breast Implants and Connective-Tissue Disease-Reply
Charles H. Hennekens,I-Min Lee,Nancy R. Cook,Patricia R. Hebert,Elizabeth W. Karlson,Fran LaMotte,JoAnn E. Manson,Julie E. Buring +7 more
TL;DR: The issue of the importance of considering atypical connective-tissue diseases such as fibromyalgia, an issue that had not been hypothesized when the Mayo Clinic was hypothesized, is raised.